Author

Amol Pendse

Institution: Glenmark Pharmaceuticals (India)

Observed institution: Glenmark Pharmaceuticals (India)

ORCID: 0000-0001-6333-7098

Observed ORCID: 0000-0001-6333-7098

OpenAlex ID: A5065469040

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

2020 · Zarir F. Udwadia, Pawan Singh, et al. · International Journal of Infectious Diseases · 293

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

2020 · Mala Dharmalingam, S. R. Aravind, et al. · Drugs · 56

SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial

2022 · Monika Tandon, Wen Wu, et al. · The Lancet Regional Health - Southeast Asia · 35

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

2021 · Sundeep Salvi, Akash Balki, et al. · ERJ Open Research · 13

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting

2022 · Pavan Kumar Reddy, Saiprasad Patil, et al. · International Journal of General Medicine · 8

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD

2022 · Sundeep Salvi, Manish K. Jain, et al. · Lung India · 2

Efficacy and Safety of a Combination of Remogliflozin Etabonate and Vildagliptin as Fixed Doses in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind Study. (FOREVER STUDY)

2024 · Paramesh Shamanna, FOREVER INVESTIGATORS, et al. · Current Trends in Internal Medicine · 1

Correction to “SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial”

2022 · Monika Tandon, Wen Wu, et al. · The Lancet Regional Health - Southeast Asia · 1

Efficacy and safety of novel nebulized combination of glycopyrronium, formoterol and budesonide in comparison with metered dose inhaler of glycopyrronium, formoterol and budesonide in COPD – A randomized, double-blind, double-dummy clinical trial

2026 · Rahul Kodgule, Sunil Jagdale, et al. · Respiratory Medicine

Patient-reported improvement in dyspnea with novel Single Nebulised Triple Therapy versus Single Inhaler Triple Therapy in elderly vs non-elderly COPD Patients: A subgroup analysis of an Indian phase III study

2026 · Divya Bhojwani, Sagar Bhagat, et al. · European Respiratory Journal

Efficacy of Bilastine, Dextromethorphan, and Phenylephrine Syrup in Patients With Dry Cough: A Phase 3 Randomised Trial

2024 · Rahul Kodgule, Pankaj Magar, et al. · Cureus

Works count: 11

Citation count: 409

H-index: 5

I10-index: 4